Transforming 
Possibilities into Reality 

OUR MISSION

At Avalon, we believe that nurturing next generation healthcare solutions is the key to improving lives around the world

That is why, since our founding in 2013, we have been striving to develop and deliver new biomedical technologies. By leveraging our extensive network of investors and industry partners, we support innovators throughout the entire journey, from academic research, funding, to building the necessary commercialization framework for the final products to helping them achieve market success.

Headquartered in Hong Kong, the Avalon group is backed by the enormous economic potential of the Greater Bay Area (GBA), the fast-growing innovation and technology hub in Southern China that’s drawing start-ups from all over Asia. Here, our dedicated management team work tirelessly with the brightest minds in biomedical technology to develop first-in-class healthcare solutions that are of the highest quality and reliability. The four pillars of our business — public health and infection control, diagnostic platforms, medical device, and pharmaceutical — ensure that we are strategically focused on areas that can help address some of the world’s most pressing medical needs.

OUR STRATEGIC FOCUS

WHAT'S NEW

June 28, 2024
EVDL is proud to have Avalon Automated Multiplex System (AAMST) in the “World Health Organization (WHO) Compendium of Innovative Health Technologies for Low-Resource Settings 2024”
May 28, 2024
Hong Kong Baptist University (HKBU) project receives support from RAISe+, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem
April 18, 2024
Emerging Viral Diagnostics (HK) Limited Receives 2023 The Hong Kong Institution of Engineers (Manufacturing, Industrial and Systems Division) – New Industrialization Award (Gold Award)
January 15, 2024
Hong Kong-based Emerging Viral Diagnostics (HK) Limited Receives Prestigious “2023 Deloitte China Life Sciences & Healthcare Rising Star” Award
View All